Primary Biliary Cholangitis Trial, Not Yet Recruiting (NCT05462093)

Primary Biliary Cholangitis Trial, Not Yet Recruiting NCT05462093 Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Condition: Primary Biliary Cholangitis

Printed from Voxsanity (voxsanity.com.au) — NCT05462093 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Primary Biliary Cholangitis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with Primary Sclerosing Cholangitis (PSC), a liver condition affecting the bile ducts, confirmed using standard medical guidelines
You are 18 years old or older
You are able to understand and agree to take part in the study by giving your consent

Who may not be able to join:

You have previously had a liver transplant
You have a known allergy to the dye (contrast agent) used in MRI scans, have a device or implant in your body that is not safe to use with an MRI machine, or have severe claustrophobia (fear of enclosed spaces) that has previously caused you to be unable to complete an MRI scan

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Cyriel Ponsioen, Prof MD PhD, Gastroenterologist and hepatologist

Phone: +31648510414

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05462093

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase: Not Applicable

Status: Not Yet Recruiting

Condition: Primary Biliary Cholangitis

Trial contact: +31648510414

More information: https://clinicaltrials.gov/study/NCT05462093

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with Primary Sclerosing Cholangitis (PSC), a liver condition affecting the bile ducts, confirmed using standard medical guidelines
You are 18 years old or older
You are able to understand and agree to take part in the study by giving your consent

Who may not be able to join:

You have previously had a liver transplant
You have a known allergy to the dye (contrast agent) used in MRI scans, have a device or implant in your body that is not safe to use with an MRI machine, or have severe claustrophobia (fear of enclosed spaces) that has previously caused you to be unable to complete an MRI scan

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Not Yet Recruiting

Phase

Not Applicable

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Registry

ClinicalTrials.gov

Start date

1 July 2022

Est. completion

1 July 2028

Primary endpoints

Delta of cT1 in patients with PSC during follow-up

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov